

Biosimilars: Where we've been and where we're headed

Sonia T. Oskouei, PharmD, BCMAS, DPLA

Vice President, Biosimilars Cardinal Health

October 7, 2022

© 2022 Cardinal Health. All Rights Reserved.



Objectives

- Discuss the current U.S. biosimilars landscape and market dynamics
- Review the U.S. biosimilars pipeline
- Understand recent policy activity that may influence biosimilar utilization
- Review various resources to support effective management of biosimilar products




Why biosimilars matter to the U.S. healthcare system



Why Biosimilars Matter to U.S. Healthcare System

Biologics economic impact

Biologics are the most expensive drug category in the U.S. and world



The U.S. has the highest pharmaceutical prices in the world. In 2018, the US accounted for 58% of global drug sales, but only 24% of volume.

Economic burden associated with oncology care

Biologics used for treating many oncology related diseases may cost over \$100,000 per year

Mulcahy W et al. International Prescription Drug Price Comparisons. RAND Corporation. www.rand.org/pubs/research_reports/RR2956.html. Accessed July 19, 2021 2. AJMC. Utilizing Oncology Biosimilars to Minimize the Economic Burden Associated with Cancer Treatmen https://www.ajmc.com/view/utilizing-oncology-biosimilars-to-minimize-the-economic-burden-associated-with-cancer-treatment-mana Accessed Oct. 3, 2022


Pharmaceutical prices in the U.S.





Why Biosimilars Matter to U.S. Healthcare System

Biosimilars target drugs with highest spending



Top Drugs by Overall Expenditure in 2021 ²				
	Name	Category	2021 Expenditure	
1	Humira (adalimumab)	Immunology	28,498M	
2	Eliquis (apixaban)	Anticoagulant	15,795M	
3	Trulicity (dulaglutide)	Diabetes	12,198M	
4	Ozempic (semaglutide)	Diabetes	10,718M	
5	Stelara (ustekinumab)	Immunology	10,682M	
6	Lantus (insulin glargine)	Diabetes	10,027M	
7	Keytruda (pembrolizumab)	Oncology	9,861M	
8	Biktarvy (bictegravir/ emtricitabine/tenofovir/ alafenamide)	HIV	9,570M	
9	Enbrel (etanercept)	Immunology	8,095M	
10	Jardiance (empagliflozin)	Diabetes	8,022M	
11	Xarelto (rivaroxaban)	Anticoagulant	7,135M	
12	Januvia (sitagliptin)	Diabetes	6,407M	
13	Novolog (insulin aspart)	Diabetes	6,043M	
14	Humalog (insulin lispro)	Diabetes	5,701M	
15	Dupixent (dupilumab)	Immunology	5,605M	
16	Immune globulin	Blood	5,371M	
17	Cosentyx (secukinumab)	Immunology	4,613M	
18	Victoza (liraglutide)	Diabetes	4,546M	
19	Epinephrine	Hormone	4,382M	
20	Opdivo (nivolumab)	Oncology	4,223M	

© 2022 Cardinal Health. All Rights Reserved. 5

Reference: 1. Aitken M, Kleinrock M, Muñoz E. Biosimilars in the United States 2020-2024: competition, savings, and sustainability. IQVIA. September 29, 2020. https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-unitedstates-2020-2024 2. Tichy EM, Schumock GT, Hoffman JM, et al. National trends in prescription drug expenditures and projections for 2020. Am J Health Syst Pharm. 2020;77(15):1213-1230. https://pubmed.ncbi.nlm.nih.gov/32412055/

= has biosimilar approved or in pipeline

CardinalHealth

U.S. biosimilar market dynamics



US Biosimilar market dynamics and pipeline

Current U.S. biosimilars landscape

Significant growth in the past two years

U.S. market as of Oct 2022:

39 FDA-approved biosimilars; **23** commercially available •

New biosimilar approvals during 2022

- Releuko Amneal filgrastim biosimilar
- Alymsys Amneal **bevacizumab biosimilar**
- Vegzelma Celltrion **bevacizumab biosimilar**
- Fylnetra Amneal **pegfilgrastim biosimilar**
- Stimufend Fresenius Kabi pegfilgrastim biosimilar
- Cimerli Coherus ranibizumab biosimilar •



2022 Cardinal Health Biosimilars Report. Available at: www.cardinalhealth.com/en/product-solutions/pharmaceutical-products/biosimilars/biosimilars-report.html.





Overall U.S. biosimilars market share

Product	Category	1 st biosimilar launch	Current # biosimilar competitors	Biosimilar market share (July 2022)
Neupogen (filgrastim)	Supportive Care	2015	2 ¹	93% ¹
Remicade (infliximab)	Immunology	2016	3	42%
Epogen/Procrit (epoetin alfa)	Supportive Care	2018	1	43%
Neulasta (pegfilgrastim)	Supportive Care	2018	4 ²	42%
Avastin (bevacizumab)	Oncology	2019	2 ³	80%
Herceptin (trastuzumab)	Oncology	2019	5	64%
Rituxan (rituximab)	Oncology	2019	3	69%
Lantus (insulin glargine)	Diabetes	2020*	14	9%
Lucentis (ranibizumab)	Ophthalmology	2022	2	0%
9 Product Classes			23	
Humira (adalimumab)	Immunology	2023	7	Not Launched
Enbrel (etanercept)	Immunology	2029	2	Not Launched

1Includes Teva's Granix, which is technically not a biosimilar since it was filed prior to the enactment of the Biosimilar Approval Pathway. Amneal's Releuko has not launched yet. 2Amneal's Fylnetra has not launched yet; Fresenius Kabo's stimufend has not launched yet

3Amneal's Alymsys has not launched yet; Celltrion Vegzelma has not launched yet

4Excludes Basaglar and yet to be launched Rezvoglar

*Neulasta Syr. Only biosimilars share is 77%


Note: italicized represents approved biosimilars that have not launched in the U.S. yet



Considerations for biosimilar adoption in the U.S. cannot be generalized across products

Biosimilar considerations vary by:

- Therapeutic area (e.g., oncology vs rheumatology vs endocrinology)
- Site of care (e.g., inpatient vs outpatient, community practice vs health system)
- Treatment type (e.g., disease modifying vs supportive care)
- Institution type (e.g., 340B vs non-340B, value- based care participation)
- Product type (e.g., buy-and-bill vs retail)
- Manufacturer commercialization strategy







Perceptions on biosimilar prescribing continue to vary by specialty

Strong biosimilar acceptance and utilization in oncology

- >70% of surveyed oncologists feel comfortable switching between biosimilars
- Majority of surveyed oncologists feel Ο comfortable switching patients to biosimilars for both curative and palliative intent

Greater hesitation with biosimilar utilization (generally or in switching scenarios) within rheumatology and ophthalmology







		25%	
5%	7 %		-
			2%



Provider Willingness to Prescribe Biosimilars for Existing Patients on Reference Biologics Has Significantly Increased








Biosimilar and brand manufacturer strategies vary


Biosimilar strategy examples

- Brand-like approach
- *Market similar* with *wrap-around services* (e.g., patient hub services)
- Multiple distribution channels
- Contracting/sourcing programs



Brand strategy examples

- Payer rebates for preferred status
- Portfolio/"basket" contracts
- Pricing strategies vary (see ASP chart)
- Innovative administration forms or combination products
- Patent protections




- Rituxan
- Ruxience
- Riabni
- Truxima



Strong correlations between biosimilar adoption and payer coverage activity

• As an example, there is a 97% correlation between Rituxan biosimilars adoption and the percentage of plans covering Rituxan biosimilars at parity or in preferred positions.




TO O



Biosimilars pipeline and opportunities in oncology





The number of biologics facing biosimilar competition will more than *double* by 2026

=has a biosimilar candidate that is seeking interchangeability designation

© 2022 Cardinal Health. All Rights Reserved. 15

Source: IPD Analytics. Market & Financial Insights. December 2021. https://www.ipdanalytics.com.

Source: 2022 Cardinal Health Biosimilars Report: the U.S. journey and path ahead. Cardinal Health. Published Feb 2022. Available at: https://www.cardinalhealth.com/en/product-solutions/pharmaceuticalproducts/biosimilars/biosimilars-report.html



Additional 2022 oncology biosimilar approvals

- 3rd filgrastim biosimilar
 - Amneal's Releuko
- 3rd and 4th bevacizumab biosimilars
 - Amneal's Alymsys
 - Celltrion's Vegzelma
- 5th pegfilgrastim biosimilar
 - Fresenius Kabi's Stimufend

Snapshot of additional oncology biosimilars activity:

Launched reference product/current biosimilars	Pending biosimilars in 2022
Avastin (bevacizumab)	
Biosimilars: Mvasi (Bevacizumab-awwb) Zirabev (Bevacizumab-bvzr)	BEVZ92 (Amneal) – Q2 2022 BAT1706 (Bio-Thera) – Q4 2022 FKB238 (Centus/AstraZeneca) – SB8 (Organon/Samsung) – peno Bmab-100 (Viatris/Biocon) – pen
Epogen/Procrit (epoetin alfa)	
Biosimilars: Retacrit (epoetin alfa-epbx)	
Herceptin (trastuzumab)	
Biosimilars: Herzuma (trastuzumab-pkrb) Kanjinti (trastuzumab-anns) Ogivri (trastuzumab-dkst) Ontruzant (trastuzumab-dttb) Trazimera (trastuzumab-qyyp)	
aunched reference product/current biosimilars	Pending biosimilars in 2022
Neulasta syringe (pegfilgrastim)	
Biosimilars: Jdenyca (pegfilgrastim-cbqv) Fulphila (pegfilgrastim-jmdb) Ziextenzo (pegfilgrastim-bmez) Nyvepria (pegfilgrastim-apgf)	Lupifil-P (Lupin) – Q2 2022 MSB11455 (Fresenius Kabi) – pending a TPI-120 (Adello) – pending approval
Neupogen (filgrastim)	
Biosimilars: Sranix† Zarxio (Filgrastim-sndz) Nivestym (Filgrastim-aafi)	TX-01 (Tanvex) – Q2-Q3 2022 Filgrastim Kashiv (Adello/Kashiv) – pend
Rituxan (rituximab)	
tiosimilars: liabni (rituximab-arrx) luxience (rituximab-pvvr)	

† Not a biosimilar

Truxima (rituximab-abbs)

Ri

Pending biosimilars – launch TBD

TRS003 (TeRuisi)

: – pending approval ading approval anding approval

APO-EPO (Apotex)

EG12014 (Sandoz) HD201 (Prestige) TX05 (Tanvex)

Pending biosimilars – launch TBD

approval

Lapelga Neupeg (Apotex/Accord)


iding approval

SAIT101 (Archigen/AZ) MabionCD20 DRL RI (Dr. Reddy's)



The biosimilar pipeline will continually replenish as biologics continue to lose exclusivity







Policy Activity



Inflation Reduction Act signed into law August 16, 2022

Prescription drug proposals include:

Require the federal government to negotiate prices for some drugs covered under Medicare Part B and Part D with the highest total spending, beginning in 2026

Require drug companies to pay rebates to Medicare if prices rise faster than inflation for drugs used by Medicare beneficiaries, beginning in 2023

Cap out-of-pocket spending for Medicare Part D enrollees and make other Part D benefit design changes, beginning in 2024

Eliminate cost sharing for adult vaccines covered under Medicare Part D and improve access to adult vaccines in Medicaid and CHIP, beginning in 2023

Expand eligibility for full benefits under the Medicare Part D Low-Income Subsidy Program, beginning in 2024

Further delay implementation of the Trump Administration's drug rebate rule, beginning in 2027

Limit monthly cost sharing for insulin to \$35 for people with Medicare, beginning in 2023



Temporary Increase in Medicare Part B **Payment for Certain Biosimilar Products**

Inflation Reduction Act signed into law August 16, 2022

- Under section 11403 of the Inflation Reduction Act, Medicare payment for certain biosimilar biological products is required to be the average sales price (ASP) plus 8 percent (rather than 6 percent) of the ASP of the reference biological for a 5 year period defined in the statute.
- A qualifying biosimilar biological product is defined as a biosimilar with an ASP that is not more than the ASP of the reference biological.
- In accordance with these provisions, the ASP Drug Pricing File reflects the temporary increased • amount for qualifying biosimilar biological products for a period of 5 years beginning with the October 2022 file.

October 1, 2022 through December 31, 2027.



Leveraging U.S. biosimilars experiences thus far to prepare for future biosimilar launches

Policy activities to ensure a conducive environment for high quality, lower cost treatment options (e.g., cost-savings emphasis and alignment of incentives)



A successful biosimilars market will enable the investment necessary to bring the next generation of innovative treatments to patients



Strategies & resources for effective biosimilars management



Essential considerations for effective biosimilars management

Clinical considerations

Provider confidence and clinical comfort

Patient/Caretaker confidence in safety and efficacy

Patient counseling and education

Financial Considerations	Operational Co
Product purchase costs	Procurement a
Reimbursement rates	Product storage
Patient out-of-pocket costs	Prior authorizat efficiencies
Patient assistant or copay programs	EHR and order



Ability to adopt/utilize outpatient infused biosimilars are ultimately dictated by payer landscape

Commercial insurers often utilize formulary management tools to control costs and utilization of products

Considerations

and inventory management

ge and refrigeration

ation and workflow

set maintenance



Payer policies can vary by region, patient, and product depending on the time of year



Cardinal Health is dedicated to managing costs and enhancing care with biosimilars

With a broad access to biosimilars and a deep understanding of the considerations for biosimilar utilization, Cardinal Health is positioned to be your trusted healthcare advisor and partner



Access to biosimilars through multiple distribution channels



Clinical resources and tools to support evaluation and adoption of biosimilars




Education and market insights



Dedicated biosimilars resources and access to subject matter experts

Biosimilars are on track to reduce U.S.

View resources at cardinalhealth.com/biosimilars



Biosimilars—a fast-growing class of therapeutic products that are highly similar to and have no clinically meaningful differences from existing FDA-approved branded biologics-are poised to significantly change the face of medicine in oncology rheumatology, diabetes and many other disease categories




drug expenditure by **\$133 billion** by 2025¹

1. Association for Accessible Medicines. (2021, October). 2021 U.S. Generic and Biosimilar Medicines Savinas Report. Retrieved from Association for Accessible Medicines: Generics & Biosimilars: https://accessiblemeds.org/sites/default/files/2021-10/AAM-2021-US-Generic-Biosimilar-Medicines-Savings-Report-web.pdf



Navigating the biosimilars payer landscape

Cardinal Health has invested in Payer Intelligence tools to help enhance visibility to commercial payer policies



Payer coverage – New Jersey region

Payer	Covered Lives	% of Market	Largest Channel
Horizon BCBS Commercial	2,106k	25.4%	Commercial
Horizon NJ Health Managed Medicaid	1,036k	12.5%	Managed Medicaid
UnitedHealthcare Commercial	941k	11.3%	Commercial
Aetna Commercial	780k	9.4%	Commercial
MAC Jurisdiction L	624k	7.5%	Medicare
Cigna Commercial	493k	5.9%	Commercial
UnitedHealthcare Community Plan Managed Medicaid NJ	365k	4.4%	Managed Medicaid
Amerigroup Managed Medicaid New Jersey	234k	2.8%	Managed Medicaid
UnitedHealthcare Medicare	187k	2.3%	Medicare
Horizon BCBS Health Exchange	168k	2.0%	Health Exchange
Top 10 Totals	6.9M	83.5%	Various

CardinalHealth

Coverage Insights

Top ten health plans in the New Jersey have various access requirements for rituximab molecule usage

Plan	Channel	Lives	% of Market	Biosimilar Step Req
Horizon BCBS Commercial	Commercial	2,105,974	25.4%	1 of Ruxience or Truxima
Horizon NJ Managed Medicaid	Managed Medicaid	1,035,710	12.5%	No step requirements, parity c
UnitedHealthcare Commercial	Commercial	940,983	11.3%	1 of Ruxience or Truxima
Aetna Commercial	Commercial	780,103	9.4%	Truxima
MAC Jurisdiction L	Medicare	624,462	7.5%	Parity coverage, PA only requir
Cigna Commercial	Commercial	492,550	5.9%	Riabni, Ruxience, and Truxima
UnitedHealthcare Community Plan Managed Medicaid NJ	Managed Medicaid	365,304	4.4%	1 of Ruxience or Truxima
Amerigroup Managed Medicaid	Managed Medicaid	233,619	2.8%	Riabni
UnitedHealthcare Medicare	Medicare	187,382	2.3%	1 of Ruxience or Truxima
Horizon BCBS Health Exchange	Health Exchange	167,768	2.0%	1 of Ruxience or Truxima
Top Ten Payers	Various	6,933,855	83.5%	Various

*This information is derived from third party sources and is provided 'as is.'

Cardinal Health makes no representations or warranties regarding the accuracy or completeness of such third-party information

quirements

coverage


ired for Riabni

a all preferred



Cardinal Health Biosimilar Resources

CardinalHealth.com/biosimilars





FDA Resources and Regulatory Activities

27-page HHS report, Comprehensive Plan for Addressing High Drug Prices mentions biosimilars >90 times

FDA educational resources for both providers and patients: FDA biosimilars website

New: Curriculum Materials for Health Care Degree Programs | Biosimilars

Congress passed two bills in 2021:

Advancing Education on Biosimilars Act

• Calls for a website "to provide educational materials for health care providers, patients, and caregivers, regarding the meaning of the terms, and the standards for review and licensing of, biological products, including biosimilar biological products and interchangeable biosimilar biological products."

Ensuring Innovation Act

• "Provide clarity for drug exclusivity to prevent awarding market exclusivity to products that do not represent true innovation and unduly delay cheaper generics from entering the market."

Biosimilars are safe and effective biologic medications for treating many illnesses such as chronic skin and bowel diseases, arthritis, kidney conditions and cancer.

are compared to another medication the original biologic.







Thank you!

© 2022 Cardinal Health. All Rights Reserved.

